Terms: = Small Cell Lung Cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Diagnosis
86 results:
1. Non-small cell lung carcinoma with clear cell features: a clinicopathologic, immunohistochemical, and molecular study of 31 cases.
Suster DI; Ronen N; Mejbel HA; Harada S; Mackinnon AC; Suster S
Virchows Arch; 2024 Jul; 485(1):83-96. PubMed ID: 38814477
[TBL] [Abstract] [Full Text] [Related]
2. The potential role of circular RNAs -regulated PI3K signaling in non-small cell lung cancer: Molecular insights and clinical perspective.
Kahkesh S; Khoshnazar SM; Gholinezhad Y; Esmailzadeh S; Hosseini SA; Alimohammadi M; Mafi A
Pathol Res Pract; 2024 May; 257():155316. PubMed ID: 38692125
[TBL] [Abstract] [Full Text] [Related]
3. Discriminative and prognostic significance of LINC00623 for lung adenocarcinoma.
Lin Y; Dong C; Zhang J; Zhu Y
Ann Biol Clin (Paris); 2024 Feb; 81(6):591-601. PubMed ID: 38391164
[TBL] [Abstract] [Full Text] [Related]
4. Menthol induces apoptosis and inhibits proliferation and migration of nonsmall cell lung carcinoma in vitro and in vivo through akt pathway.
Liu Z; Li C; Mu L; Hu H; Qin X
Clin Respir J; 2023 Dec; 17(12):1265-1275. PubMed ID: 38012058
[TBL] [Abstract] [Full Text] [Related]
5. CircHERC1 promotes non-small cell lung cancer cell progression by sequestering FOXO1 in the cytoplasm and regulating the miR-142-3p-HMGB1 axis.
Cui Y; Wu X; Jin J; Man W; Li J; Li X; Li Y; Yao H; Zhong R; Chen S; Wu J; Zhu T; Lin Y; Xu J; Wang Y
Mol Cancer; 2023 Nov; 22(1):179. PubMed ID: 37932766
[TBL] [Abstract] [Full Text] [Related]
6. CCL2 promotes metastasis and epithelial-mesenchymal transition of non-small cell lung cancer via PI3K/akt/mTOR and autophagy pathways.
Xu H; Wang J; Al-Nusaif M; Ma H; Le W
Cell Prolif; 2024 Mar; 57(3):e13560. PubMed ID: 37850256
[TBL] [Abstract] [Full Text] [Related]
7. BATF2 inhibits PD-L1 expression and regulates CD8+ T-cell infiltration in non-small cell lung cancer.
Liu J; Li J; Tuo Z; Hu W; Liu J
J Biol Chem; 2023 Nov; 299(11):105302. PubMed ID: 37777155
[TBL] [Abstract] [Full Text] [Related]
8. [PHF5A Promotes Proliferation and Migration of Non-small cell lung cancer
by Regulating of PI3K/akt Pathway].
Wang H; Liu F; Bai C; Xu N
Zhongguo Fei Ai Za Zhi; 2023 Jan; 26(1):10-16. PubMed ID: 36792075
[TBL] [Abstract] [Full Text] [Related]
9. Relationship between the microRNAs and PI3K/akt/mTOR axis: Focus on non-small cell lung cancer.
Lin Y; Zhang L; Ding X; Chen C; Meng M; Ke Y; Wang W
Pathol Res Pract; 2022 Nov; 239():154093. PubMed ID: 36183437
[TBL] [Abstract] [Full Text] [Related]
10. miR-29b Regulates lung cancer Progression by Downregulating FEM1B and Inhibiting the FOX01/akt Pathway.
Zhang H; Wang R; Deng Q
Comput Math Methods Med; 2022; 2022():3110330. PubMed ID: 36003920
[TBL] [Abstract] [Full Text] [Related]
11. Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access.
Florez MA; Kemnade JO; Chen N; Du W; Sabichi AL; Wang DY; Huang Q; Miller-Chism CN; Jotwani A; Chen AC; Hernandez D; Sandulache VC
Cancer Res Commun; 2022 Jul; 2022(8):806-13. PubMed ID: 35966167
[TBL] [Abstract] [Full Text] [Related]
12. MIR4435-2HG Is a Potential Pan-cancer Biomarker for diagnosis and Prognosis.
Zhong C; Xie Z; Zeng LH; Yuan C; Duan S
Front Immunol; 2022; 13():855078. PubMed ID: 35784328
[TBL] [Abstract] [Full Text] [Related]
13. LINC00665: An Emerging Biomarker for cancer Diagnostics and Therapeutics.
Zhong C; Xie Z; Shen J; Jia Y; Duan S
Cells; 2022 May; 11(9):. PubMed ID: 35563845
[TBL] [Abstract] [Full Text] [Related]
14. LINC00963: A potential cancer diagnostic and therapeutic target.
Xie Z; Zhong C; Shen J; Jia Y; Duan S
Biomed Pharmacother; 2022 Jun; 150():113019. PubMed ID: 35462329
[TBL] [Abstract] [Full Text] [Related]
15. Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction.
Vadla GP; Daghat B; Patterson N; Ahmad V; Perez G; Garcia A; Manjunath Y; Kaifi JT; Li G; Chabu CY
Sci Rep; 2022 Apr; 12(1):6693. PubMed ID: 35461372
[TBL] [Abstract] [Full Text] [Related]
16. Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers.
Liu CY; Lin HF; Lai WY; Lin YY; Lin TW; Yang YP; Tsai FT; Wang CL; Luo YH; Chen YM; Hsu PK; Kai LJ; Kiat AOH; Chien Y; Chiou SH; Wang CY
J Chin Med Assoc; 2022 Apr; 85(4):409-413. PubMed ID: 35383703
[TBL] [Abstract] [Full Text] [Related]
17. Combined metabolomics with transcriptomics reveals potential plasma biomarkers correlated with non-small-cell lung cancer proliferation through the akt pathway.
Zheng J; Zheng Y; Li W; Zhi J; Huang X; Zhu W; Liu Z; Gong L
Clin Chim Acta; 2022 May; 530():66-73. PubMed ID: 35245482
[TBL] [Abstract] [Full Text] [Related]
18. Dysregulated
Sui J; Zhao Q; Zhang Y; Liang G
DNA Cell Biol; 2022 Mar; 41(3):319-329. PubMed ID: 35244469
[TBL] [Abstract] [Full Text] [Related]
19. A 10-year retrospective study of lung cancer in Uganda.
Bogere N; Bongomin F; Katende A; Omaido BA; Namukwaya E; Mayanja-Kizza H; Walusansa V
BMC Cancer; 2022 Feb; 22(1):204. PubMed ID: 35197014
[TBL] [Abstract] [Full Text] [Related]
20. Targeting Neuregulin 1 (NRG1): A Novel Biomarker for Non-small-cell lung cancer.
Fang C; Kang B; Zhao P; Ran J; Wang L; Zhao L; Luo H; Tao L
J Environ Pathol Toxicol Oncol; 2021; 40(4):61-72. PubMed ID: 34936301
[TBL] [Abstract] [Full Text] [Related]
[Next]
